Bronchioloalveolar adenocarcinoma (BAC) is a type of lung cancer that originates in the cells lining the bronchioles and alveoli, the airways and air sacs of the lungs, respectively. It is a subtype of adenocarcinoma, the most common form of lung cancer.
Bronchioloalveolar adenocarcinoma is characterized by the abnormal growth of glandular cells that line the airways and alveoli. Unlike other types of lung cancer, BAC tends to grow along the airway walls and often spreads through the air sacs, rather than invading surrounding tissues or forming solid tumors. This unique growth pattern can lead to a more indolent or slow-growing tumor, resulting in a better overall prognosis compared to other lung cancers.
Symptoms of bronchioloalveolar adenocarcinoma may include persistent cough, shortness of breath, chest pain, and coughing up blood. However, some individuals with BAC may present with no symptoms, making early detection challenging.
Treatment options for bronchioloalveolar adenocarcinoma depend on factors such as the extent of the disease, the individual's overall health, and their treatment preferences. Surgical removal of the tumor, radiation therapy, and chemotherapy are common treatment approaches. In recent years, targeted therapies and immunotherapies have also shown promise as treatments for some cases of BAC.
Regular monitoring and follow-up care are essential for individuals diagnosed with bronchioloalveolar adenocarcinoma to assess tumor growth, response to treatment, and to manage any side effects.
